Compare Stocks: EPRX, LKFT, VIR, and AGIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$31.81 -0.3%	$33.13	$22.24 ▼ $46.00	$1.91B	0.63	1.16 million shs	835,676 shs
EPRX Eupraxia Pharmaceuticals	$7.46 -1.5%	$7.51	$5.25 ▼ $9.32	$492.19M	0.83	910,640 shs	1.05 million shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$29.73 +0.7%	$28.51	$25.68 ▼ $36.24	$1.94B	0.24	383,777 shs	212,541 shs
VIR Vir Biotechnology	$11.70 +5.2%	$10.47	$4.82 ▼ $12.00	$1.88B	1.59	2.36 million shs	1.97 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	-0.34%	+0.03%	-8.14%	-22.85%	-25.33%
EPRX Eupraxia Pharmaceuticals	-1.45%	+3.04%	-7.67%	+11.68%	+21.50%
LKFT Lakefront Biotherapeutics American Depositary Shares	+0.75%	+1.23%	+8.38%	-1.78%	-13.83%
VIR Vir Biotechnology	+5.22%	+4.74%	+8.23%	+17.47%	+93.39%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$31.81 -0.3%	$33.13	$22.24 ▼ $46.00	$1.91B	0.63	1.16 million shs	835,676 shs
EPRX Eupraxia Pharmaceuticals	$7.46 -1.5%	$7.51	$5.25 ▼ $9.32	$492.19M	0.83	910,640 shs	1.05 million shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$29.73 +0.7%	$28.51	$25.68 ▼ $36.24	$1.94B	0.24	383,777 shs	212,541 shs
VIR Vir Biotechnology	$11.70 +5.2%	$10.47	$4.82 ▼ $12.00	$1.88B	1.59	2.36 million shs	1.97 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	-0.34%	+0.03%	-8.14%	-22.85%	-25.33%
EPRX Eupraxia Pharmaceuticals	-1.45%	+3.04%	-7.67%	+11.68%	+21.50%
LKFT Lakefront Biotherapeutics American Depositary Shares	+0.75%	+1.23%	+8.38%	-1.78%	-13.83%
VIR Vir Biotechnology	+5.22%	+4.74%	+8.23%	+17.47%	+93.39%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.55	Moderate Buy	$41.50	30.46% Upside
EPRX Eupraxia Pharmaceuticals	2.90	Moderate Buy	$17.80	138.61% Upside
LKFT Lakefront Biotherapeutics American Depositary Shares	2.56	Moderate Buy	$37.00	24.45% Upside
VIR Vir Biotechnology	2.67	Moderate Buy	$21.86	86.81% Upside

Current Analyst Ratings Breakdown

Latest EPRX, LKFT, VIR, and AGIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2026	EPRX Eupraxia Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
10/7/2026	AGIO Agios Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$39.00 ➝ $37.00
10/7/2026	VIR Vir Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$20.00 ➝ $22.00
10/6/2026	VIR Vir Biotechnology	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
10/2/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
10/2/2026	VIR Vir Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/1/2026	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$11.00
9/28/2026	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy
9/24/2026	EPRX Eupraxia Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$25.00
9/24/2026	EPRX Eupraxia Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$17.00
9/23/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$98.34M	19.31	N/A	N/A	$20.46 per share	1.55
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	$1.41 per share	N/A
LKFT Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.56	$0.73 per share	40.64	$47.57 per share	0.62
VIR Vir Biotechnology	$68.56M	28.88	N/A	N/A	$5.50 per share	2.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	-$412.78M	-$7.01	N/A	N/A	N/A	-418.24%	-35.67%	-33.06%	11/5/2026 (Estimated)
EPRX Eupraxia Pharmaceuticals	-$38.58M	-$1.02	N/A	N/A	N/A	N/A	-63.97%	-43.32%	11/3/2026 (Estimated)
LKFT Lakefront Biotherapeutics American Depositary Shares	$363.05M	-$1.41	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	-$437.99M	-$1.86	N/A	N/A	N/A	N/A	-29.99%	-23.62%	11/4/2026 (Estimated)

Latest EPRX, LKFT, VIR, and AGIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	AGIO Agios Pharmaceuticals	-$1.24	N/A	N/A	N/A	$51.95 million	N/A
11/4/2026	Q3 2026	VIR Vir Biotechnology	-$0.7393	N/A	N/A	N/A	$0.87 million	N/A
11/3/2026	Q3 2026	EPRX Eupraxia Pharmaceuticals	-$0.26	N/A	N/A	N/A	N/A	N/A
8/11/2026	Q2 2026	EPRX Eupraxia Pharmaceuticals	-$0.25	-$0.23	+$0.02	-$0.23	N/A	N/A
8/10/2026	Q2 2026	LKFT Lakefront Biotherapeutics American Depositary Shares	-$0.9672	$0.03	+$0.9972	$0.0330	$7.29 million	$15.47 million
8/5/2026	Q2 2026	VIR Vir Biotechnology	$0.3326	$0.47	+$0.1374	$0.47	$135.88 million	$238.95 million
7/30/2026	Q2 2026	AGIO Agios Pharmaceuticals	-$1.65	-$1.69	-$0.04	-$1.69	$26.40 million	$44.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	10.22	9.79
EPRX Eupraxia Pharmaceuticals	0.02	16.00	16.00
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	32.84	32.72
VIR Vir Biotechnology	N/A	6.04	6.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
EPRX Eupraxia Pharmaceuticals	N/A
LKFT Lakefront Biotherapeutics American Depositary Shares	32.46%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	5.40%
EPRX Eupraxia Pharmaceuticals	N/A
LKFT Lakefront Biotherapeutics American Depositary Shares	2.91%
VIR Vir Biotechnology	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	540	59.70 million	56.48 million	Optionable
EPRX Eupraxia Pharmaceuticals	49	65.02 million	N/A	N/A
LKFT Lakefront Biotherapeutics American Depositary Shares	1,310	65.90 million	63.98 million	Optionable
VIR Vir Biotechnology	367	169.22 million	164.31 million	Optionable

EPRX, LKFT, VIR, and AGIO Headlines

Recent News About These Companies

VIR-5500 Receives FDA Fast Track Designation for Late-Line Metastatic CRPC

October 10 at 9:50 AM | cancernetwork.comC

Vir Biotechnology’s T-cell engager ‘VIR-5500’ gets US FDA’s fast track designation to treat prostate cancer

October 10 at 9:50 AM | pharmabiz.comP

Vir Biotechnology (NASDAQ:VIR) Sets New 1-Year High - What's Next?

October 10 at 3:41 AM | americanbankingnews.com

Vir Biotechnology (NASDAQ:VIR) Hits New 52-Week High - Here's What Happened

October 10 at 3:39 AM | marketbeat.com

Prostate and Rare Cancer Agents Nab FDA Fast Track Status

October 9 at 6:47 PM | targetedonc.comT

Chutes & Ladders—Vir looks to Liu to lead late-stage push

October 9 at 6:47 PM | fiercebiotech.comF

Vir Biotechnology stock hits 52-week high at 11.96 USD

October 9 at 6:47 PM | ca.investing.com

Vir Biotechnology (NASDAQ:VIR) Shares Climb 6.1% - Here's Why

October 9 at 11:59 AM | marketbeat.com

Vir Biotechnology, Inc. Announces Appointment of David Liu as Executive Vice President and Chief Medical Officer, Effective October 12, 2026

October 9 at 8:46 AM | marketscreener.comM

Vir Biotechnology, Inc. and Astellas Pharma Inc. Announce FDAFast Track Designation for PSMA-Targeted Pro-XTEN® Dual-Masked T-Cell Engager VIR-5500 for the Treatment of ...

October 9 at 8:46 AM | marketscreener.comM

Vir Biotechnology's VIR-5500 Gets FDA Fast Track Designation for Prostate Cancer

October 9 at 8:46 AM | finance.yahoo.com

What is HC Wainwright's Forecast for VIR FY2028 Earnings?

October 9 at 6:56 AM | marketbeat.com

HC Wainwright Forecasts Strong Price Appreciation for Vir Biotechnology (NASDAQ:VIR) Stock

October 9 at 2:36 AM | americanbankingnews.com

Vir Biotechnology (NASDAQ:VIR) Shares Down 6.5% - Here's What Happened

October 8 at 12:39 PM | marketbeat.com

How Upcoming SOLSTICE Phase 2 HDV Data Could Shape Vir Biotechnology’s (VIR) Investment Narrative

October 8 at 7:42 AM | finance.yahoo.com

Vir Biotechnology (NASDAQ:VIR) Stock Rating Lowered by Zacks Research

October 8 at 6:06 AM | americanbankingnews.com

Vir Biotechnology (NASDAQ:VIR) Cut to "Strong Sell" at Zacks Research

October 8 at 6:05 AM | marketbeat.com

uniQure (NASDAQ:QURE) and Vir Biotechnology (NASDAQ:VIR) Financial Survey

October 8 at 4:15 AM | americanbankingnews.com

Vir Biotechnology stock gained 5.46 percent before SOLSTICE data

October 7 at 11:40 AM | ad-hoc-news.deA

Vir Biotechnology appoints David Liu as chief medical officer

October 7 at 11:40 AM | seekingalpha.com

Vir Biotechnology (NASDAQ:VIR) Given New $22.00 Price Target at HC Wainwright

October 7 at 10:47 AM | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EPRX, LKFT, VIR, and AGIO Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$31.81 -0.11 (-0.34%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$31.82 +0.01 (+0.03%)

As of 10/9/2026 07:31 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$7.46 -0.11 (-1.45%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$7.64 +0.18 (+2.41%)

As of 10/9/2026 07:30 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

$29.73 +0.22 (+0.75%)

As of 10/9/2026 04:00 PM Eastern

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Vir Biotechnology NASDAQ:VIR

$11.70 +0.58 (+5.22%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$11.62 -0.08 (-0.67%)

As of 10/9/2026 07:56 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EPRX, LKFT, VIR, and AGIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EPRX, LKFT, VIR, and AGIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EPRX, LKFT, VIR, and AGIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EPRX, LKFT, VIR, and AGIO Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Eupraxia Pharmaceuticals NASDAQ:EPRX

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

Vir Biotechnology NASDAQ:VIR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EPRX, LKFT, VIR, and AGIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EPRX, LKFT, VIR, and AGIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EPRX, LKFT, VIR, and AGIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EPRX, LKFT, VIR, and AGIO Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Eupraxia Pharmaceuticals NASDAQ:EPRX

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

Vir Biotechnology NASDAQ:VIR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools